This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

Watch Sanjay popat discuss the QoL results of the LUX-Lung 3 trial!

GIOTRIF® (afatinib) significantly improved dyspnoea and some pain symptoms compared with pemetrexed/cisplatin1

LUX-Lung 3: Median TTD of symptoms. EORTC QoLQLQ-C30 and QLQ LC-13

  • More patients (≥50%) on GIOTRIF® (afatinib) experienced clinically meaningful improvements in pre-specified tumour symptoms (dyspnoea, pain and cough)1

GIOTRIF® (afatinib) delayed time to worsening of clinically relevant symptoms versus pemetrexed/cisplatin1

Compared with chemotherapy, GIOTRIF® (afatinib) delayed time to deterioration of cough (27 vs 8 months, P=0.006), dyspnoea (10.4 vs 2.9 months, P=0.013) and pain (4.2 vs 3.1 months, P=0.188), respectively2

GIOTRIF® (afatinib) significantly improved QoL versus pemetrexed/cisplatin1

Global health status and functioning. EORTC QoLQLQ-C30 questionnaire scores longitudinal analysis

  • GIOTRIF® (afatinib) had significantly better mean QoL scores over time for global health status/QoL, physical role, and cognitive functioning1

CI=confidence interval; EGFR M+=epidermal growth factor receptor mutation positive; EORTC=European Organisation for Research and Treatment of Cancer; QoL=quality of life; TTD=time to deterioration, the time from randomisation to first appearance of a score ≥10 points lower than the baseline score.

You may be interested in: 

Learn how Frank Griesinger's patient benefited from switching to afatinib from chemotherapy!

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Yang et al., The Lancet Oncology, Volume 16, Issue 2, February 2015, Pages 141-151

Download the publication!

Is this information compelling to you?

Request contact
from Boehringer Ingelheim


  1. Yang JC et al. J Clin Oncol. 2013;31(27):3342-3350.
  2. Wu YL et al. Poster presented at: ESMO Congress; Madrid, Spain; 26-30 September 2014.
  3. Yang JC et al. Lancet Oncol. 2015;16(2):141-151.
  4. Schuler M et al. J Thorac Oncol. 2016;11(3):380-390.
  1. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.

  2. Wu YL et al. Lancet Oncol. 2014;15(2):213-222.

  3. Yang JC et al. Lancet Oncol. 2015;16(2):141-151.

  4. Park K et al. Lancet Oncol. 2016;17(5):577-589.

  5. Soria JC et al. Lancet Oncol. 2015;16(8):897-907.

  6. Solca F et al. J Pharmacol Exp Ther. 2012;343(2):342-350.

  7. Yang JC et al. J Clin Oncol. 2013;31(27):3342-3350.

  8. Hirsch V et al. Poster #369 presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA; 3-7 June 2016.

  9. Yang JCH et al. Ann Oncol. 2016;27(11):2103-2110.

  10. Schuler M et al. J Thorac Oncol. 2016;11(3):380-390.

  11. Paz-Arez L et al. Ann Oncol. 2017; doi: 10.1093/annonc/mdw611.

  12. GIOTRIF® (afatinib) Summary of Product Characteristics, 2016.

Report an adverse event

If you wish to report an adverse event (AE) after treatment with one of our products, please select your site from the link below. This will allow reporting of AEs in line with the reporting procedure effective in your country for reporting.

Boehringer Ingelheim local websites
Back to top